This blog explores the benefits of applying Large Language Models to extract information from pathology reports, allowing us to curate bespoke ...

BOSTON & MONTREAL, February 04, 2025--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage ...

“These study results demonstrate the potential for sasanlimab in combination with BCG to redefine the treatment paradigm for patients living with BCG-naïve, high-risk non-muscle invasive bladder ...

J&J on Wednesday said the application covers TAR-200 in Bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors.

In bladder cancer, IBRX has worked to pursue ... rather than just those patients with carcinoma in situ, which represents a minority of patients with NMIBC. IBRX has phase 2 trials ongoing for ...

Urinary tract infection, bladder tumors, carcinoma in situ, bladder stones, and interstitial cystitis must also be considered and ruled out when appropriate. The principle of treatment of urinary ...

Tislelizumab plus low-dose nab-paclitaxel “demonstrated enduring efficacy while maintaining a manageable safety profile,” according to researchers.

The drugmaker is seeking to have the therapy approved for the treatment of Bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer with carcinoma in situ, with or ...

high-risk non-muscle invasive bladder cancer, including patients with carcinoma in-situ (CIS), providing prolonged event-free survival which may delay or reduce the need for more aggressive ...

The "Bladder Cancer Diagnostics Market by Test Type, by Stages, by Cancer Type, by End User, and By Region" report has been ...